86results about How to "Suitable for oral" patented technology

The present invention provides methods of treating cancers, chemoprevention, selectively inducing terminal differentiation, cell growth arrest and / or apoptosis of neoplastic cells, and / or inhibiting histone deacetylase (HDAC) by administration of pharmaceutical compositions comprising potent HDAC inhibitors. The oral bioavailability of the active compounds in the pharmaceutical compositions of the present invention is surprisingly high. Moreover, the pharmaceutical compositions unexpectedly give rise to high, therapeutically effective blood levels of the active compounds over an extended period of time. The present invention further provides a safe, daily dosing regimen of these pharmaceutical compositions, which is easy to follow, and which results in a therapeutically effective amount of the HDAC inhibitors in vivo.

The present invention provides methods of treating cancers, chemoprevention, selectively inducing terminal differentiation, cell growth arrest and / or apoptosis of neoplastic cells, and / or inhibiting histone deacetylase (HDAC) by administration of pharmaceutical compositions comprising potent HDAC inhibitors. The oral bioavailability of the active compounds in the pharmaceutical compositions of the present invention is surprisingly high. Moreover, the pharmaceutical compositions unexpectedly give rise to high, therapeutically effective blood levels of the active compounds over an extended period of time. The present invention further provides a safe, daily dosing regimen of these pharmaceutical compositions, which is easy to follow, and which results in a therapeutically effective amount of the HDAC inhibitors in vivo.

The present invention relates to the Bifidobacterium CECT 7765 strain, to its cell components, metabolites, and secreted molecules, to the combinations thereof with other microorganisms, and to compositions comprising the aforementioned products, as well as to the use of a strain of the Bifidobacterium pseudocatenulatum species, or to using the CECT 7765 strain for the prevention and / or treatment of obesity, overweight, hyperglycemia and diabetes, preferably type 2 diabetes mellitus, hepatic steatosis or fatty liver, dyslipidemia, metabolic syndrome, immune system dysfunction associated with obesity and overweight; and an unbalanced composition of the intestinal microbiota associated with obesity and overweight.

Methods for treating mesothelioma comprising administering the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) are disclosed.

The invention relates to biparatopic A-beta binding polypeptides and, more specifically, to biparatopic A-beta binding polypeptides comprising at least two immunoglobulin single variable domains binding to different epitopes of A-beta. The invention also relates to specific sequences of such polypeptides, methods of their production, and methods of using them, including methods of treatment of diseases such as Alzheimer's Disease.

The invention relates to an L-carnitine calcium fumarate and a preparation method and usages thereof. The L-carnitine calcium fumarate is characterized by oral intake, stability and no-hygroscopicity, and has stronger and more functions of nutrition and treatment, compared with corresponding internal salt and good water solubility; the preparation method is: the calcium furmarate is dissolved in the water and added with calcic alkali for reaction with the temperature increasing to 70 to 90 DEG C for 2 to 8 hours and then water is evaporated by reducing pressure. The solid obtained by drying is added into ethanol and evenly mixed, with the L-carnitine added for reaction with the temperature at 60 to 70 DEG C for 1 to 6 hours, then the mixture is put into a refrigerator for refrigeration for 2 to 8 hours and the L-carnitine calcium fumarate is finally obtained by suction and filtration; the composition containing the L-carnitine calcium fumarate can be made into one or more excipients acceptable on pharmacology, particularly solid and liquid oral intake preparation, such as powdered drug, granules, tablets, capsules, oral liquid, etc., is preferred and the solid and liquid oral intake preparation can be used for food / nutrition additives for people, or feed additives for animals, including additives for calcium supplement.

Disclosed are packaged compositions comprising an aseptically sterilized container and a sterilized, concentrated, nutritional liquid emulsion that is aseptically packaged and sealed within the container. Also disclosed are methods for making and using the packaged compositions. In some embodiments, the aseptically packaged, concentrated, nutritional liquid emulsions have a desirable flavor and aroma and have increased emulsion stability.

The present invention relates to veterinary compositions in a form of an orally deliverable tablet, and more particularly to a controlled-release composition that provides sufficiently long duration to permit once daily administration.

The invention relates to glycyrrhetinic acid solid lipid nanoparticles and a preparation method for the same, belonging to the field of medicinal preparation. The main ingredients of the glycyrrhetinic acid solid lipid nanoparticles disclosed by the invention comprise active raw material glycyrrhetinic acid, medicinal phospholipid, a lipid material and a surfactant. The glycyrrhetinic acid solid lipid nanoparticle solution and the freeze-dried powder injection thereof prepared by the preparation method disclosed by the invention are small in particle diameter, high in entrapment efficiency, good in stability and capable of being used for a plurality of administration routes such as oral administration and injection administration. The glycyrrhetinic acid solid lipid nanoparticles disclosed by the invention can reduce dosage, enhance curative effect and reduce the toxic and side effects of medicine, as well as are suitable for treating a plurality of diseases such as hepatitis, liver cancer, lung cancer, ovarian cancer, gastritis, gastric cancer, leukaemia and aids.

The present invention relates to a new pharmaceutical composition containing nicotinic acid, nicotinamide, tryptophanor related compounds for positively influencing the intestinal microbiota. In certain embodiments, the pharmaceutical composition is partially or entirely released into the small intestine or large intestine.

An embodiment of the present invention relates to a compound of the general formula. The compound of formula is suitable for use in a method for treating a disorder relating to the binding of a galectin, such as galectin-3 to a ligand in a mammal, such as a human. Furthermore an embodiment of the present invention concerns a method for treatment of a disorder relating to the binding of a galectin, such as galectin-3 to a ligand in a mammal, such as a human.

A calcium citrate salt and its preparation method and application are disclosed. The calcium citrate salt has stronger nutritional and therapeutical effects than simple calcium citrate. The preparation method comprises the following steps: dissolving citric acid in water, adding calcium oxide or calcium hydrate or calcium carbonate, filtering to remove foreign materials after the solution is dissolved to be transparent, adding L-arginine or L-lysine or acetyl L-carnitine or propionyl l-carnitine into a filtrate, reacting at 0-100 DEG C for 2-8 h, carrying out vacuum concentration, cooling, carrying out crystallization by adding anhydrous ethanol, filtering and drying, and detecting to be qualified so as to obtain the product. A composition containing the calcium citrate salt can be made into one or more pharmacologically acceptable excipients, especially a solid-liquid oral preparation, such as pulvis, a particulate agent, a tablet, capsules and an oral liquid, etc., or directly made into a beverage, and can be used as dietary / nutritional supplement for human or a feed supplement for animals, including nutritional supplements for supplementing L-arginine, L-lysine, acetyl L-carnitine and propionyl L-carnitine.

The invention discloses a medicine composition for treating diabetes. The medicine comprises the following components in parts by weight: 5-15 parts of longan seeds, 5-15 parts of lichee seeds, 5-10 parts of mulberry, 3-8 parts of pawpaw seeds, 3-10 parts of radix astragali and 5-10 parts of rhizoma polygonati. The components of the formulation of the medicine composition for treating diabetes are simple and scientifically, rationally formulated, the medicine has remarkable efficacy, short course, small toxic and side effect and long efficacy, is suitable for diabetic patients of variable types for administration, is suitable for oral administration, and is convenient, safe and reliable.

This disclosure relates to formulations and methods of suppressing appetite and eliciting satiety (sense of being filled) in mammals through the oral administration of an effective amount of an appetite suppressing moiety.

The invention discloses an oral emulsion rich in [alpha]-linolenic acid. The oral emulsion is prepared from the following components in percentage by weight: 1-25% of plant oil containing the [alpha]-linolenic acid, 1-25% of an emulsifier, 0.1-20% of adjuvants, 0.001-5% of an antioxidant, 0-1.5% of flavoring agent and the balance of purified water; and the plant oil containing the [alpha]-linolenic acid is extracted from the following components in parts by weight: 20-25 parts of eucommia ulmoides oliver seeds, 10-15 parts of perilla seeds, 10-15 parts of kiwi fruit seeds, 12-17 parts of peony seeds, 10-16 parts of linseed and 7-12 parts of Chinese prickly ash seeds. The invention also discloses a preparation method of the oral emulsion rich in the [alpha]-linolenic acid. The oral emulsion containing the [alpha]-linolenic acid prepared by the invention is stable in ingredient, high in bioavailability, free from toxic and side effects, obvious in curative effect, broad in application to indications and obvious in social and economic values, and bad smell and taste of the oil can be masked.

Composition comprising leucine, isoleucine, valine, threonine and lysine for use in prophylactic and / or therapeutic treatment of renal disorders in a subject, preferably an elderly subject.

The invention discloses lactobacillus plantarum 550 with constipation relieving and sleep aiding functions and application of lactobacillus plantarum 550, belonging to the technical field of biology. The lactobacillus plantarum 550 provided by the invention is preserved in the China Center for Type Culture Collection on December 21, 2007, wherein the accession number of the lactobacillus plantarum 550 is CCTCC No. M 207202. The lactobacillus plantarum 550 provided by the invention is applied to preparation of functional food and medicines for relieving constipation, or / and helping sleep, or / and reducing cholesterol, or / and inhibiting pathogenic bacteria, or / and degrading nitrite. The lactobacillus plantarum 550 grows well and quickly on an MRS agar culture medium, is high in acid production capacity, has good gastric acid and cholate tolerance, and can be colonized in intestinal tracts. The lactobacillus plantarum 550 has a good bowel relaxing effect, strong capability of producing gamma-aminobutyric acid, the effect of reducing cholesterol in vitro, a good inhibition effect on common pathogenic bacteria, capability of rapidly degrading nitrite and the good safety.

The present invention is directed to novel pharmaceutical combinations including compositions and kits comprising bretylium as the active ingredient, as well as methods for preventing and / or treating conditions related to the cardiovascular system using such novel pharmaceutical combinations.

The invention relates to flumatinib mesylate crystal form B and a preparation method and the use thereof. One crystal form of the flumatinib mesylate, the preparation method thereof, medicine combination of the compound and with treatment effective quantity and application of the crystal form in preparation of medicine for treating chronic myelogenous leukemia are further provided.

A means and method for treating malaria, schistosomiasis, and cancer using a spiro or dispiro 1,2,4-trioxolane is described. The preferred 1,2,4-trioxolanes include a spiroadamantane group on one side of the trioxolane group, and a spirocyclohexyl on the other side of the trioxolane group. In comparison to artemisinin semisynthetic derivatives, the compounds of this invention are structurally simple, easy to synthesize, non-toxic, and potent against malarial parasites. The compounds of the invention unexpectedly provide a single-dose cure for malaria, as well as prophylactic activity against the same. The compounds are also active against schistosomiasis and cancer.

The invention belongs to the technical field of medicines and particularly relates to an artemether oral micro-emulsion in-situ gel and a preparation method thereof. The artemether oral micro-emulsionin-situ gel is prepared from the following components of 0.1-0.8% of artemether, 0.9-7.2% of oil phases, 0.4-12% of surfactants, 0.4-12% of cosurfactants, 0.23-0.3% of in-situ gel substrates, 0-0.1%of adhesives and the balance water. The average particle size of emulsion drops of the artemether oral micro-emulsion in-situ gel is 20.90 nm, the emulsion drops are uniform in size, the solubility and releasing rate of the artemether can be increased, and the artemether oral micro-emulsion in-situ gel is stable at the room temperature; the artemether oral micro-emulsion in-situ gel is low in viscosity and good in flowability, the gel is formed immediately in a stomach after oral administration, the detention time of the artemether in the stomach can be prolonged, treatment of a stomach cancerand improving of the bioavailability of the artemether are facilitated; and the preparation technique is easy, operation and filling are easy, and industrial production is facilitated.

L-carnitine calcium fumarate and its preparation and applications are disclosed in the present invention. Having good water solubility as well as better and stronger nutritious and treating functions than the corresponding inner salts, the L-carnitine calcium fumarate as proposed having the advantages of being non-hygroscopic, stable in chemical property, and suitable for oral administration. A preparing method is as follow: fumaric acid is suspended in water and calcium base is added. The resulting mixture is heated up to 70˜90° C. and kept under stirring for 2˜8 hours, and then concentrated under reduced pressure. The resulting dried substance is added into ethanol, and the mixture is vigorously stirred. The inner salt of L-carnitine is added, and the mixture is reacted for 1-6 hours at 60˜70° C. and then cooled for 2˜8 hours. L-carnitine calcium fumarate is obtained by filtration.

The invention relates to a traditional Chinese medicine composition for treating chronic prostatitis and a preparation method thereof. The traditional Chinese medicine composition is prepared from thefollowing raw materials in parts by weight: 8 to 12 parts of cortex eucommiae chlorogenic acid, 6 to 10 parts of cortex cinnamomi polyphenol, 13 to 17 parts of oyster peptide, 8 to 12 parts of maca,8 to 12 parts of cordyceps militaris, 13 to 17 parts of silk peptide, 2 to 6 parts of herba abelmoschi esculenti, 2 to 6 parts of cortex pausinystaliae macroceras, 2 to 6 parts of catuaba, 2 to 6 parts of herba epimedii, 2 to 6 parts of herba gynostemmatis, 2 to 6 parts of herba rhodiolae, 2 to 6 parts of radix salviae miltiorrhizae and 2 to 6 parts of semen persicae. The traditional Chinese medicine composition disclosed by the invention is simple in preparation and remarkable in curative effect, has no side effect, is safe and effective, is low in cost and is suitable for oral administration.

An embodiment of the present invention relates to a compound of the general formula. The compound of formula is suitable for use in a method for treating a disorder relating to the binding of a galectin, such as galectin-3 to a ligand in a mammal, such as a human. Furthermore an embodiment of the present invention concerns a method for treatment of a disorder relating to the binding of a galectin, such as galectin-3 to a ligand in a mammal, such as a human.

The invention relates to flumatinib mesylate crystal form A and a preparation method and the use thereof. Specifically, one crystal form of the flumatinib mesylate, the preparation method thereof, medicine combination of the compound and with treatment effective quantity and application of the crystal form in preparation of medicine for treating chronic myelogenous leukemia are further provided.